gadobenate dimeglumine (Multihance)
Jump to navigation
Jump to search
Introduction
Tradename: Multihance (FDA-approved in 2004)
Indications
- used in magnetic resonance imaging (MRI) of the central nervous system (CNS)
Adverse effects
- may be less likely to cause nephrogenic systemic fibrosis than other gadolinium-based MRI contrast agents[2]
Mechanism of action
- paramagnetic agent
Notes
Manufacturer: Bracco
More general terms
References
- ↑ Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210216&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Jump up to: 2.0 2.1 Martin DR et al. No incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease. Radiology 2018 Jan; 286:113 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28731375 <Internet> http://pubs.rsna.org/doi/10.1148/radiol.2017170102